Novel, first-in-class, fatty acid synthase inhibitor, TVB-2640 demonstrates robust clinical efficacy and safety in a global Phase 2 randomized placebo-controlled NASH trial conducted in the US and China

Conference Reports for NATAP

The Liver Meeting
Digital Experience
AASLD
November 13 - 16 - 2021


Novel, first-in-class, fatty acid synthase inhibitor, TVB-2640 demonstrates robust clinical efficacy and safety in a global Phase 2 randomized placebo-controlled NASH trial conducted in the US and China

	AASLD 2021 Nov 12-15